Study on Ceftazidime-Avibactam with Aztreonam Combination Treatment in Carbapenem-Resistant Klebsiella pneumoniae in Tertiary Care Hospital in India

Christina, Sharon; Praveena, Raveendran

doi:10.30699/ijmm.18.4.257

year 18, Issue 4 (July - August 2024) Iran J Med Microbiol 2024, 18(4): 257-264 | Back to browse issues page

‎ 10.30699/ijmm.18.4.257

Mendeley

Zotero

RefWorks

Christina S, Praveena R. Study on Ceftazidime-Avibactam with Aztreonam Combination Treatment in Carbapenem-Resistant Klebsiella pneumoniae in Tertiary Care Hospital in India. Iran J Med Microbiol 2024; 18 (4) :257-264
URL: http://ijmm.ir/article-1-2393-en.html

Study on Ceftazidime-Avibactam with Aztreonam Combination Treatment in Carbapenem-Resistant Klebsiella pneumoniae in Tertiary Care Hospital in India

Sharon Christina¹

, Raveendran Praveena²

1- Department of Microbiology, Sree Balaji Medical College and Hospital, Bharath Institute of Higher Education and Research, Chennai, India , drchristinam@gmail.com
2- Department of Microbiology, Sree Balaji Medical College and Hospital, Bharath Institute of Higher Education and Research, Chennai, India

Abstract: (788 Views)

Background and Objective: Recently, the rise in various carbapenemases in Enterobacteriaceae poses a significant challenge to the healthcare systems and limits the treatment options. This study aimed to evaluate different assays such as disc diffusion, VITEK, and Rapidec® Carba NP test for the carbapenemase detection, and investigate the synergistic effects of ceftazidime-avibactam (CAZ/AVI) and aztreonam (AZM) combination therapy using the E-strip method.
Methods: This prospective study was conducted on the samples collected from January 2023 to February 2024 at the Department of Microbiology, Central Laboratory Sree Balaji, Medical College and Hospital Chennai, India. The isolates were cultured and identified using the standard biochemical methods followed by the antibiotic susceptibility testing (AST) both by Kirby Bauer disc diffusion (DD) and the VITEK^®2 system. The Rapidec® Carba NP test was performed in detecting carbapenemase. The efficacy and potential synergistic effects of the combination treatment comprising CAZ/AVI and AZM were performed using the E-strip gradient stacking method.
Results & Conclusion: According on the AST, the highest resistance rates were detected for ampicillin (78%), then, followed by amoxicillin/clavulanic acid (52%), meropenem (56%), imipenem (56%), cefazolin (56%), and ciprofloxacin (53%). The lowest resistance rates were found for gentamicin (23%), cotrimoxazole (27%), piperacillin/tazobactam (27%), and tobramycin (33%). Rapidec® Carba NP test detected 65 bacterial isolates stored in the laboratory, resulting in a sensitivity of 97% for carbapenemase detection. For carbapenem-resistant Klebsiella pneumoniae (CRKP) isolates, synergy was observed between CAZ/AVI E-strip and AZM E-strip in 66 out of 67 isolates (98.75%). The Rapidec® Carba NP test remains a valuable tool for the initial screening, providing timely information for the clinicians. The high rate of synergy observed in our study suggests that CAZ/AVI and AZM will provide a promising treatment option for the CRKP infections, particularly in the settings with limited therapeutic alternatives.

Keywords: Carbapenem-resistant Klebsiella pneumoniae, Ceftazidime-Avibactam with Aztreonam combination, Rapidec® Carba NP test, MIC

Full-Text [PDF 713 kb] (290 Downloads) | | Full-Text (HTML) (135 Views)

Type of Study: Brief Original Article | Subject: Medical Bacteriology
Received: 2024/06/26 | Accepted: 2024/09/22 | ePublished: 2024/09/29

References

1. Salawudeen A, Raji YE, Jibo GG, Desa MN, Neoh HM, Masri SN, et al. Epidemiology of multidrug-resistant Klebsiella pneumoniae infection in clinical setting in South-Eastern Asia: a systematic review and meta-analysis. Antimicrob Resist Infect Control. 2023;12(1):142. [DOI:10.1186/s13756-023-01346-5]

2. Ghasemshahi S, Ahmadpor M, Booskabadi A, Rezaei H, Poopak B, Hakemi-Vala M. A six-month survey of the frequency of extensively drug-resistant gram-negative bacteria by VITEK 2 system in 2020. Iran J Med Microbiol. 2022;16(2):134-40. [DOI:10.30699/ijmm.16.2.134]

3. Camargo CH, Yamada AY, De Souza AR, Cunha MP, Ferraro PS, Sacchi CT, et al. Genomic analysis and antimicrobial activity of β-lactam/β-lactamase inhibitors and other agents against KPC-producing Klebsiella pneumoniae clinical isolates from Brazilian hospitals. Sci Rep. 2023;13(1):14603. [DOI:10.1038/s41598-023-41903-x]

4. Sree RA, Gupta A, Gupta N, Veturi S, Reddy LS, Begum M, et al. Ceftazidime-avibactam alone or in combination with aztreonam versus polymyxins in the management of carbapenem-resistant Klebsiella pneumoniae nosocomial infections (CAPRI study): a retrospective cohort study from south India. Infection. 2024;52(2):429-37. [DOI:10.1007/s15010-023-02094-9]

5. Karki D, Dhungel B, Bhandari S, Kunwar A, Joshi PR, Shrestha B, et al. Antibiotic resistance and detection of plasmid mediated colistin resistance mcr-1 gene among Escherichia coli and Klebsiella pneumoniae isolated from clinical samples. Gut Pathog. 2021;13(1):45. [DOI:10.1186/s13099-021-00441-5]

6. Rajan R, Rao AR, Kumar MS. Ceftazidime-avibactam/aztreonam combination synergy against carbapenem-resistant Gram-negative isolates: In vitro study. Curr Med Res Pract. 2024;14(1):16-21. [DOI:10.4103/cmrp.cmrp_189_23]

7. Liu S, Lin Q, Ouyang L, Zhou C, Wang H. Successful treatment of ceftazidime/avibactam combined with aztreonam in the NDM-producing Klebsiella pneumoniae bloodstream and intestinal infections in a NK/T lymphoma patient with agranulocytosis during autologous hematopoietic stem cell transplantation: a case report. Eur. J Clin Microbiol Infect Dis. 2022:1-4. [DOI:10.1007/s10096-022-04523-3]

8. Bakthavatchalam YD, Walia K, Veeraraghavan B. Susceptibility testing for aztreonam plus ceftazidime/avibactam combination: A general guidance for clinical microbiology laboratories in India. Indian J Med Microbiol. 2022;40(1):3-6. [DOI:10.1016/j.ijmmb.2021.12.006]

9. Bocanegra-Ibarias P, Camacho-Ortiz A, Garza-González E, Flores-Treviño S, Kim H, Perez-Alba E. Aztreonam plus ceftazidime-avibactam as treatment of NDM-1-producing Klebsiella pneumoniae bacteraemia in a neutropenic patient: Last resort therapy?. J Glob Antimicrob Resist. 2020;23:417-9. [DOI:10.1016/j.jgar.2020.10.019]

10. Kashkouri N, Tabarsi P, Pourabdollah Toutkaboni M, Kazempour Dizaji M, Bahrami N, et al. The Prevalence of Carbapenemase Genes in Carbapenem-resistant Gram-negative Bacilli, Masih Daneshvari Hospital, Tehran, Iran, 2019-2020. Iran J Med Microbiol. 2022;16(6):573-80. [DOI:10.30699/ijmm.16.6.573]

11. Seyfi B, Hossainpour H, Kooti S, Azizi Jalilian F. Identification of Carbapenem Resistance Genes in Escherichia coli Isolated from Blattella germanica by Dot Blot Assay in Hamadan Hospitals, Iran-2018. Iran J Med Microbiol. 2022;16(4):357-62. [DOI:10.30699/ijmm.16.4.357]

12. Vamsi SK, Moorthy RS, Hemiliamma MN, Reddy RB, Sirikonda S. Phenotypic and genotypic detection of carbapenemase production among gram negative bacteria isolated from hospital acquired infections. Saudi Med J. 2022;43(3):236. [DOI:10.15537/smj.2022.43.3.20210809]

13. Mokhtari M, Mojtahedi A, Mahdieh N, Jafari A, Arya MJ. High prevalence of blaOXA-48 and blaNDM-producing carbapenem-resistant Klebsiella pneumoniae isolated from clinical samples in shahid rajaei hospital in tehran, Iran. Jundishapur J Microbiol. 2022;15(10):e130804. [DOI:10.5812/jjm-130804]

14. Kansak N, Çalık Ş, Arıcı N, Adaleti R, Aksaray S, Gönüllü N. Performance of the Rapidec® Carba NP assay for the detection of different carbapenemases in Klebsiella pneumoniae and Escherichia coli strains. Indian J Med Microbiol. 2022;40(4):516-20. [DOI:10.1016/j.ijmmb.2022.08.004]

15. Dortet L, Agathine A, Naas T, Cuzon G, Poirel L, Nordmann P. Evaluation of the RAPIDEC® CARBA NP, the Rapid CARB Screen® and the Carba NP test for biochemical detection of carbapenemase-producing Enterobacteriaceae. J Antimicrob Chemother. 2015;70(11):3014-22. [DOI:10.1093/jac/dkv213]

16. Vamsi KS, Ramamoorthy S, Murali TS, Singh M, Kabra V. Utility of Carba NP test (Inhouse/RAPIDEC Commercial Kit) in the Identification of Carbapenemase Producing Clinical Isolates in a Tertiary Care Hospital. J Clin Diagn Res. 2019;13(12). [DOI:10.7860/JCDR/2019/42780.13375]

17. Khan A, Erickson SG, Pettaway C, Arias CA, Miller WR, Bhatti MM. Evaluation of Susceptibility Testing Methods for Aztreonam and Ceftazidime-Avibactam Combination Therapy on Extensively Drug-Resistant Gram-Negative Organisms. 2021;65(11):10-128. [DOI:10.1128/AAC.00846-21]

18. Maraki S, Mavromanolaki VE, Moraitis P, Stafylaki D, Kasimati A, Magkafouraki E, et al. Ceftazidime-avibactam, meropenen-vaborbactam, and imipenem-relebactam in combination with aztreonam against multidrug-resistant, metallo-β-lactamase-producing Klebsiella pneumoniae. Eur J Clin Microbiol Infect Dis. 2021;40(8):1755-9. [DOI:10.1007/s10096-021-04197-3]

19. Jayol A, Nordmann P, Poirel L, Dubois V. Ceftazidime/avibactam alone or in combination with aztreonam against colistin-resistant and carbapenemase-producing Klebsiella pneumoniae. J Antimicrob Chemother. 2018;73(2):542-4. [DOI:10.1093/jac/dkx393]